The miR-17-92 cluster as a potential biomarker for the early diagnosis of gastric cancer: evidence and literature review.
The miR-17-92 cluster as a potential biomarker for the early diagnosis of gastric cancer: evidence and literature review.
复制标题
miR-17-92簇作为胃癌早期诊断的潜在生物标志物：证据和文献综述
DOI：
10.18632/oncotarget.15023
复制
发表时间：
2017-07-11
期刊：
影响因子：
--
通讯作者：
Fan D
中科院分区：
文献类型：
--
作者：
Li H;Wu Q;Li T;Liu C;Xue L;Ding J;Shi Y;Fan D
肠上皮化生被认为是胃癌的一种癌前病变。先前有报道称miR - 17 - 92簇在癌症发展的预测中具有临床价值。本研究旨在检测miR - 17 - 92在胃癌和肠上皮化生患者与正常人相比的诊断价值。
结果显示，与健康对照组相比，miR - 17 - 92成员在胃癌和肠上皮化生患者的血清中均过度表达。血清miR - 17 - 92成员也能够区分胃癌和肠上皮化生患者与健康对照组。
采用实时定量聚合酶链反应检测了75例胃癌患者、104例肠上皮化生患者和38例健康对照者的血清miR - 17 - 92表达水平。然后分析受试者工作特征（ROC）曲线以及ROC曲线下面积（AUC），以检测miR - 17 - 92成员在区分胃癌、肠上皮化生和健康对照组方面的效能。
总之，miR - 17 - 92簇可能作为一种潜在的血清生物标志物用于胃癌的早期检测。
Purpose Intestinal metaplasia is considered to be a pre-cancerous lesion of gastric cancer. The miR-17-92 cluster was previously reported to have clinical value in the prediction of cancer development. This study aimed to test the diagnostic value of miR-17-92 in gastric cancer and the intestinal metaplasia patients compared with the normal ones. Results The results showed that miR-17-92 members were over-expressed in the serum of both gastric cancer and intestinal metaplasia patients, compared with healthy controls. Serum miR-17-92 members could also distinguish patients with gastric cancer and intestinal metaplasia from healthy controls. Materials and Methods Serum miR-17-92 expression levels were detected using quantitative real-time PCR in 75 patients with gastric cancer, 104 patients with intestinal metaplasia and 38 healthy controls. The Receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) were then analyzed to test the efficacy of the miR-17-92 members in distinguishing gastric cancer, intestinal metaplasia and healthy controls. Conclusions In conclusion, the miR-17-92 cluster might be useful as a potential serum biomarker for the early detection of gastric cancer.